Suivi IRM des patients SEP : pourquoi ?

Barkhof, 2002, The clinico-radiological paradox in multiple sclerosis revisited, Curr Opin Neurol, 15, 239, 10.1097/00019052-200206000-00003 Enzinger, 2015, Nonconventional MRI and microstructural cerebral changes in multiple sclerosis, Nat Rev Neurol, 11, 676, 10.1038/nrneurol.2015.194 Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 33, 1444, 10.1212/WNL.33.11.1444 Doty, 1997, Olfactory dysfunction in multiple sclerosis, N Engl J Med, 336, 1918, 10.1056/NEJM199706263362617 Charil, 2003, Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets, Neuroimage, 19, 532, 10.1016/S1053-8119(03)00117-4 Minneboo, 2004, Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis, Arch Neurol, 61, 217, 10.1001/archneur.61.2.217 Swanton, 2009, Early MRI in optic neuritis: the risk for disability, Neurology, 72, 542, 10.1212/01.wnl.0000341935.41852.82 Tintore, 2011, Brainstem lesions in clinically isolated syndromes, Neurology, 75, 1933, 10.1212/WNL.0b013e3181feb26f Wybrecht, 2012, Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis, Mult Scler, 18, 1585, 10.1177/1352458512442991 Kearney, 2015, Cervical cord lesion load is associated with disability independently from atrophy in MS, Neurology, 84, 367, 10.1212/WNL.0000000000001186 Fisniku, 2008, Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, 131, 808, 10.1093/brain/awm329 Rudick, 2006, Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study, Ann Neurol, 60, 236, 10.1002/ana.20883 Summers, 2008, Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease, J Neurol Neurosurg Psychiatry, 79, 955, 10.1136/jnnp.2007.138685 Daumer, 2009, MRI as an outcome in multiple sclerosis clinical trials, Neurology, 72, 705, 10.1212/01.wnl.0000336916.38629.43 Dalton, 2011, Brain lesion location and clinical status 20years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis, Mult Scler, 18, 322, 10.1177/1352458511420269 Bodini, 2011, T2 lesion location really matters: a 10-year follow-up study in primary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 82, 72, 10.1136/jnnp.2009.201574 Bermel, 2013, Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta, Ann Neurol, 73, 95, 10.1002/ana.23758 Dobson, 2014, Assessing treatment response to interferon-beta: is there a role for MRI?, Neurology, 82, 248, 10.1212/WNL.0000000000000036 Sormani, 2013, MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials, Lancet Neurol, 12, 669, 10.1016/S1474-4422(13)70103-0 Sormani, 2014, Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis, Ann Neurol, 75, 43, 10.1002/ana.24018 Rio, 2009, Measures in the first year of therapy predict the response to interferon beta in MS, Mult Scler, 15, 848, 10.1177/1352458509104591 Sormani, 2013, Scoring treatment response in patients with relapsing multiple sclerosis, Mult Scler, 19, 605, 10.1177/1352458512460605 Dong-Si, 2014, Outcome and survival of asymptomatic PML in natalizumab-treated MS patients, Ann Clin Transl Neurol, 1, 755, 10.1002/acn3.114 Yousry, 2012, Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy, Ann Neurol, 72, 779, 10.1002/ana.23676 Wattjes, 2013, The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy, Mult Scler, 19, 1826, 10.1177/1352458513510224 Wattjes, 2014, Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI, Curr Opin Neurol, 27, 260, 10.1097/WCO.0000000000000099 Wattjes, 2015, MRI pattern in asymptomatic natalizumab-associated PML, J Neurol Neurosurg Psychiatry, 86, 793, 10.1136/jnnp-2014-308630 Waggoner, 2009, Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant, J Heart Lung Transplant, 28, 395, 10.1016/j.healun.2008.12.010 Clifford, 2011, Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis, Arch Neurol, 68, 1156, 10.1001/archneurol.2011.103 Rosenkranz, 2015, PML in a patient with lymphocytopenia treated with dimethyl fumarate, N Engl J Med, 372, 1476, 10.1056/NEJMc1415408 Nieuwkamp, 2015, PML in a patient without severe lymphocytopenia receiving dimethyl fumarate, N Engl J Med, 372, 1474, 10.1056/NEJMc1413724 Gross, 2012, Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod, Neurology, 79, 2006, 10.1212/WNL.0b013e3182735d24 Ratchford, 2012, Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod, Neurology, 79, 2002, 10.1212/WNL.0b013e3182735d00 Leypoldt, 2009, Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report, Neurology, 72, 1022, 10.1212/01.wnl.0000344567.51394.e3 Arvin, 2015, Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management, JAMA Neurol, 72, 31, 10.1001/jamaneurol.2014.3065 Visser, 2012, Tumefactive multiple sclerosis lesions under fingolimod treatment, Neurology, 79, 2000, 10.1212/WNL.0b013e3182735cb3 Pilz, 2013, Tumefactive MS lesions under fingolimod: a case report and literature review, Neurology, 81, 1654, 10.1212/01.wnl.0000435293.34351.11